drugset / Trial / NCT05506566
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
RandomizedParallel-groupOpen-labelDiagnostic
Summary
As an emerging molecule targeting FAP, 68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-CHX in patients with various types of cancer and compared them with the results of 68Ga-FAPI-04 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-CHX.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2025-05-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 1.85 mbq/kg | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 68Ga-FAPI-04 | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |